High risks associated with the transmission of infectious diseases to pregnant women have raised concerns about effective diagnosis of various infections. As such, infectious disease testing type segment of the women’s health diagnostics market is projected to reach a value of ~US$ 19.2 Bn by the end of 2027. Hence, leading players in the market for women’s health diagnostics are increasing their efficacy in laboratory testing solutions to improve patient outcomes. For instance, leading global medical technology company Siemens Healthineers, offers a range of laboratory testing solutions for women related to TORCH (toxoplasmosis, other (e.g., syphilis, HIV), rubella, cytomegalovirus (CMV), and herpes simplex virus) infections, malnutrition, and bone diseases.
Healthcare companies in the women’s health diagnostics market are tapping into opportunities in diagnostic laboratory testing and infectious disease testing, as both the segments are anticipated to grow rapidly during the forecast period. Growing prevalence of infections causing miscarriage and birth defects in infants are fueling the demand for efficacious treatment options in women’s health diagnostics.
Strategic Mergers Offer New Reproductive Health Solutions for Asian Women
Apart from expanding product portfolios, companies in the market for women’s health diagnostics are strengthening their global presence through inorganic strategies such as mergers and acquisitions. For instance, in August 2019, Nova Satra Dx – a provider of innovative diagnostics for cancer, announced its merger with a Singapore-based molecular diagnostic company INEX Innovations Exchange Pte. Ltd., to offer healthcare solutions tailored for Asian women. As such, Asia Pacific accounts for the third-highest revenue in the women’s health diagnostics market. This market in Asia Pacific is anticipated for exponential growth during the forecast period.
Companies are collaborating to offer enhanced treatment options in Asia Pacific. Efforts are being made to increase the availability of faster and more accurate diagnostic tests to improve quality of life in patients. The concept of precision healthcare is another key driver that is creating incremental opportunities for companies. The women’s health diagnostics market is undergoing change with increased efforts toward providing women’s reproductive health solutions.
New Testing Approaches Create Revenue Opportunities for Companies and Healthcare Providers
Complications associated with cervical cancer has led to the availability of new tests for early detection of the human papillomavirus (HPV). As such, in terms of test type, the cervical cancer testing segment of the women’s health diagnostics market is estimated to reach a value of ~US$ 12.5 Bn by 2027. Hence, companies are introducing new testing options to determine the type of HPV that may lead to cancer.
Expanding operations in future? To get the perfect launch ask for a custom report
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insights to thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyse information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.